Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 04, 2015 12:32 AM ET

Life Sciences Tools and Services

Company Overview of Aegis Therapeutics, LLC

Company Overview

Aegis Therapeutics, LLC, a drug-delivery and drug-formulation technologies company, commercializes drug delivery and protein stabilization technologies to pharmaceutical and biopharmaceutical companies. It offers Intravail, a drug delivery technology that enables the non-invasive delivery of a broad range of protein, peptide, and non-peptide drugs. The company also provides ProTek to create homogeneous, stable, aqueous or lyophilized dosage forms for peptide or protein therapeutics. In addition, it offers Hydrogels, an absorption-enhancing self-assembling aqueous hydrogels for transdermal drug delivery or transmucosal application. The company was founded in 2003 and is based in San Diego, Ca...

11770 Bernardo Plaza Court

Suite 353

San Diego, CA 92128

United States

Founded in 2003

Phone:

858-618-1400

Fax:

858-618-1441

Key Executives for Aegis Therapeutics, LLC

Chief Executive Officer and Director
Executive Chairman
Age: 72
Chief Business Officer and Director
Member of Advisory Board
Compensation as of Fiscal Year 2014.

Aegis Therapeutics, LLC Key Developments

Aegis Offers Exclusive License to Develop, Commercialize, and Sell its Patented Non-Invasive Exenatide Metered Nasal Spray Diabetes Drug

Aegis announced that it is offering an exclusive license to develop, commercialize, and sell its patented non-invasive exenatide metered nasal spray diabetes drug. Exenatide is a 39-amino acid synthetic peptide GLP-1 analog highly effective in controlling blood glucose levels in Type-2 diabetes. All currently available GLP-1 analogs require injection. The currently marketed injectable form of exenatide, sold under the trademark Byetta(R), requires twice daily injections. The Aegis patented Intravail(R) based formulation of exenatide provides equivalent blood levels using a simple metered nasal spray to replace each of the two daily injections. The total market for GLP-1 analogs is expected to grow to $5 billion within the next few years. As the only non-injectable option for patients seeking to avoid needles, needlestick injuries, and syringe disposal problems, the non-injectable Aegis nasal spray exenatide formulation is poised to achieve significant market share.

Aegis Therapeutics, LLC Presents at BIO International Convention, Jun-25-2014 04:15 PM

Aegis Therapeutics, LLC Presents at BIO International Convention, Jun-25-2014 04:15 PM. Venue: San Diego Convention Center, San Diego, California, United States.

Aegis Intravail(R) Technology Enhances Oral Bioavailability of Tableted OTC Drugs

Aegis Therapeutics LLC's Intravail(R) technology has been successfully formulated with phenylephrine in compressed tablets, dramatically improving oral bioavailability by more than 50%. This is the first application of Intravail(R) in a solid dosage form. The Intravail formulation is compatible with current tableting processes employed for OTC and prescription drugs and does not alter tablet size or appearance. Previously published studies have shown that Intravail(R) alkylsaccharide excipients increase oral bioavailability of a number of peptide and nonpeptide drugs in preclinical studies. Examples include exenatide, octreotide, desmopressin, heparin, sumatriptan and a 7kDa antisense (nucleotide analog) drug. In these latter applications, Intravail was incorporated into aqueous formulations or fast dissolve or chewable formats. The extension of the use of Intravail(R) into solid dosage forms represents a significant expansion of the broad applicability of this technology. Intravail(R) excipients are equally soluble in pharmaceutically accepted oils thus permitting use as oral absorption enhancers in gel caps as well. Sixteen US and foreign patents have issued to date and Notice of Allowance has been received on two additional patents that will issue shortly covering various aspects of the Intravail(R)/ProTek(R) alkylsaccharide-based technologies. More than 50 additional patent applications are currently pending. Aegis licenses its Intravail(R) drug delivery and ProTek(R) protein stabilization technologies to biopharmaceutical companies worldwide and is now seeking licensees for the application of Intravail to a broad range of over-the-counter drugs where increased bioavailability or more rapid onset of action would offer improved performance and significant market differentiation in a crowded field.

Similar Private Companies By Industry

Company Name Region
Novum Pharmaceutical Research Services Of Nevada, Inc. United States
OpenTrons Labworks Inc. United States
Medical Products Laboratories, Inc. United States
California Healthcare Institute United States
Aureon Biosciences, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Aegis Therapeutics, LLC, please visit aegisthera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.